$VOYG @Starlab_Space Jim Bridenstine serves as Chair of the Advisory Board for Voyager and as a member of the Board of Directors for Starlab. His extensive experience as former NASA Administrator and in national security provides valuable strategic guidance as Voyager advances both its commercial space infrastructure and defense initiatives.

#AITSF イリス的循环之室loop the r∞m model:Aki/sc motion/camera:Nabix/Durles/Rellis Starlab/Daniii19i/MameKo_Sheep stage:Ai/attiemmd/NOR effect:大葉真琴/そぼろ/化身バレッタ/Rui/SaraKale/ikeno/Wind./LenXiaoA/less/舞力介入P/針金P/RaC/三金络合物

🚀 10 Space Stocks Most Investors don’t Have Exposure To But Should : 1. $KRMN – Karman Holdings: Supplies mission-critical payload protection, propulsion, and interstage systems to rockets across the industry. Deeply embedded but under the radar. 2. $BKSY – BlackSky: Real-time high-resolution (35cm) geospatial intelligence. Scaling contracts toward $100M ARR trajectory. 3. $RDW – Redwire: Pioneering in-space manufacturing zero-G 3D printing, biotech, crystals, and on-orbit production. 4. $VOYG – Voyager Technologies: Leading Starlab, the commercial space station to succeed the ISS and sustain human presence in LEO. 5. $FLY – Firefly Aerospace: First commercial company with a fully successful upright soft lunar landing (Blue Ghost). Strong backlog for follow-ons. 6. $LUNR – Intuitive Machines: Delivered the first U.S. commercial Moon landing in decades and executing ongoing NASA CLPS missions. 7. $PL – Planet Labs: Daily Earth imaging from its satellite fleet. Record revenue growth and path to sustained profitability. 8. $IRDM – Iridium: Pole-to-pole satellite coverage via its 66-satellite LEO constellation. Proven free cash flow generator. 9. $RKLB – Rocket Lab: The only public U.S. rocket company at real scale, frequent launches Neutron development. 10. $ASTS – AST SpaceMobile: Building the world’s first space-based cellular broadband network for direct-to-smartphone connectivity. 2026 outlook is explosive. Most retail investors own zero exposure. That's an indicator of opportunity.

$VOYG -BTIG initiates Voyager Technologies coverage with a Buy rating on defense growth -Notes potential upside related to Starlab -Sets $55 target m.investing.com/news/analyst…

Denver-based Voyager is working on Starlab, a proposed space station, with partners including Airbus, Mitsubishi and Palantir bloomberg.com/news/articles/…

Why do life sciences researchers conduct experiments in microgravity? One reason is that cells behave differently in space. Instead of growing in flat layers, cells can form three-dimensional structures that more closely resemble human tissue. That can give researchers a more realistic environment for studying disease and evaluating potential treatments. Microgravity can also accelerate certain biological changes, allowing researchers to observe processes related to aging and disease over shorter periods of time. These are some of the reasons microgravity has become an important tool for life sciences research. Starlab is being developed to help expand access to that research environment after the ISS era.

$VOYG "Voyager Space is not a competitor to SpaceX. SpaceX is a broad space enterprise, while Voyager is an infrastructure company that works in partnership with them. Additionally, Voyager’s Starlab is a commercial space station project built through international collaboration.

$PLTR Palantir is an official Starlab partner, and if NASA picks Starlab this month after Trump Jr. invested, PLTR will be the AI brain of the next space station launching in 2029 — VOYG is already up. 💥💥🚀 share.google/hKnrrcwmUsysItd…

$RDW ✨ The Space Race Is Coming for Pharma: Why Drug Development Is Heading to Low Earth Orbit CNBC highlights how microgravity-based pharmaceutical research is moving from experimentation toward commercialization. Key developments: ✅ Redwire's SpaceMD has flown 54 PIL-BOX units to space ✅ 37 drug compounds have already been tested in orbit ✅ Eli Lilly $LLY , Bristol Myers Squibb $BMY , and other pharmaceutical companies are participating ✅ Merck's Keytruda research on the ISS helped support development of a new injectable version approved by the FDA in 2025 Why microgravity matters: • Higher-quality protein crystals • Potentially easier drug delivery • Reduced need for lengthy hospital infusions • Improved drug stability and storage Redwire believes space can help unlock promising drug candidates that fail on Earth due to crystallization and stability challenges. As the ISS approaches retirement, commercial space stations such as Vast and Starlab are expected to become the next generation of orbital research platforms. The future of space may extend far beyond satellites and rockets — into medicine, biotechnology, and pharmaceutical manufacturing. cnbc.com/2026/06/09/space-ra… #RDW #Redwire #SpacePharma #Biotech #SpaceTech #LLY #BMY #Merck